Ausgabe 7/2010
Inhalt (26 Artikel)
ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity?
Daniele Barbaro, Frederik A. Verburg, Markus Luster, Christoph Reiners, Domenico Rubello
Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
Ahmet Bilici, Bala Basak Oven Ustaalioglu, Mesut Seker, Nesrin Canpolat, Bulent Tekinsoy, Taflan Salepci, Mahmut Gumus
Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma
Amandine Pallardy, Caroline Bodet-Milin, Aurore Oudoux, Loïc Campion, Emmanuelle Bourbouloux, Christine Sagan, Catherine Ansquer, Aude Testard, Isabelle Resche, Boumédiène Bridji, Françoise Kraeber-Bodéré, Caroline Rousseau
Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma
Ferdinand Sudbrock, Matthias Schmidt, Thorsten Simon, Wolfgang Eschner, Frank Berthold, Harald Schicha
Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer
Wenfeng Yang, Yongming Zhang, Zheng Fu, Jinming Yu, Xiaorong Sun, Dianbin Mu, Anqin Han
FDG positron emission tomography/computed tomography studies of Wilms’ tumor
A. K. M. Moinul Hossain, Barry L. Shulkin, Michael J. Gelfand, Humayun Bashir, Najat C. Daw, Susan E. Sharp, Helen R. Nadel, Jeffrey S. Dome
Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1
Mahendranath Moharir, Kevin London, Robert Howman-Giles, Kathryn North
18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence
Kimiteru Ito, Jyunkichi Yokoyama, Kazuo Kubota, Miyako Morooka, Michio Shiibashi, Hiroshi Matsuda
Optimizing the colloid particle concentration for improved preoperative and intraoperative image-guided detection of sentinel nodes in prostate cancer
Lenka Vermeeren, Sara H. Muller, Willem Meinhardt, Renato A. Valdés Olmos
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
D. Cordier, F. Forrer, F. Bruchertseifer, A. Morgenstern, C. Apostolidis, S. Good, J. Müller-Brand, H. Mäcke, J. C. Reubi, A. Merlo
68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET
Maarten Brom, Wim J. G. Oyen, Lieke Joosten, Martin Gotthardt, Otto C. Boerman
A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue
Vladimir Tolmachev, Irina Velikyan, Mattias Sandström, Anna Orlova
PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab
Tapan K. Nayak, Celeste A. S. Regino, Karen J. Wong, Diane E. Milenic, Kayhan Garmestani, Kwamena E. Baidoo, Lawrence P. Szajek, Martin W. Brechbiel
Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours
Andrew Merron, Patrick Baril, Pilar Martin-Duque, Antonio de la Vieja, Lucile Tran, Arnaud Briat, Kevin J. Harrington, Iain A. McNeish, Georges Vassaux
A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues
Rogier P. J. Schroeder, Cristina Müller, Suzanne Reneman, Marleen L. Melis, Wout A. P. Breeman, Erik de Blois, Chris H. Bangma, Eric P. Krenning, Wytske M. van Weerden, Marion de Jong
68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours
Matthias Eder, Stefan Knackmuss, Fabrice Le Gall, Uwe Reusch, Vladimir Rybin, Melvyn Little, Uwe Haberkorn, Walter Mier, Michael Eisenhut
Methodological considerations in quantification of oncological FDG PET studies
Dennis Vriens, Eric P. Visser, Lioe-Fee de Geus-Oei, Wim J. G. Oyen
PET-guided prostate cancer radiotherapy: technological innovations for dose delivery optimisation
Giovanni Lucignani, Habib Zaidi
Comment on: “FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging, version 1.0”
Babak Saboury, Drew A. Torigian, Abass Alavi
Reply to: FDG PET and PET/CT: EANM procedure guideline for tumour PET imaging
Ronald Boellaard, Mike J O’Doherty, Arturo Chiti, Bernd J. Krause
The diagnostic accuracy of 18F-FDG PET in cutaneous malignant melanoma
Bruno Krug, Anne-Sophie Pirson, Ralph Crott, Thierry Vander Borght
Reply to: The diagnostic accuracy of 18F-FDG PET in cutaneous malignant melanoma
Roberto C. Delgado-Bolton, Felisa Jiménez-Requena, Cristina Fernández-Pérez, Sanjiv S. Gambhir, Judy Schwimmer, José M. Pérez-Vázquez, José L. Carreras-Delgado
An unusual looking pacemaker infection imaged with 18F-FDG PET/CT
Sophie Turpin, Raymond Lambert, Nancy Poirier
‘Running on empty’
Damian Wild, Aikaterini Theodoraki, Tom R. Kurzawinski, Jamshed Bomanji, Jean Claude Reubi, Rehman Khan, Pierre Bouloux, Bernard Khoo
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging
Emilio Bombardieri, Valentina Ambrosini, Cumali Aktolun, Richard P. Baum, Angelica Bishof-Delaloye, Silvana Del Vecchio, Lorenzo Maffioli, Luc Mortelmans, Wim Oyen, Giovanna Pepe, Arturo Chiti